BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

April 14, 2014 7:00 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) was up $0.03 to $72.23 on Monday after FDA accepted and granted Priority Review for an NDA for an oral, once-daily, fixed-dose combination of the company's Sovaldi sofosbuvir and ledipasvir (GS-5885) to treat chronic HCV genotype 1 infection. The PDUFA date is Oct. 10. An MAA for the combination is under accelerated assessment in the EU.

Gilead was off $1.58 over the next two days, then fell $5.17 to $65.48 on Thursday amidst a decline in biotech stocks and a fall in the broader markets. The BioCentury 100 Index shed 5.6% and the NASDAQ registered a 3.1% drop on the day...